The shaping and functional consequences of the microRNA landscape in breast cancer
- PMID: 23644459
- DOI: 10.1038/nature12108
The shaping and functional consequences of the microRNA landscape in breast cancer
Abstract
MicroRNAs (miRNAs) show differential expression across breast cancer subtypes, and have both oncogenic and tumour-suppressive roles. Here we report the miRNA expression profiles of 1,302 breast tumours with matching detailed clinical annotation, long-term follow-up and genomic and messenger RNA expression data. This provides a comprehensive overview of the quantity, distribution and variation of the miRNA population and provides information on the extent to which genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture, suggesting an important role for post-transcriptional regulation. The key clinical parameters and cellular pathways related to the miRNA landscape are characterized, revealing context-dependent interactions, for example with regards to cell adhesion and Wnt signalling. Notably, only prognostic miRNA signatures derived from breast tumours devoid of somatic copy-number aberrations (CNA-devoid) are consistently prognostic across several other subtypes and can be validated in external cohorts. We then use a data-driven approach to seek the effects of miRNAs associated with differential co-expression of mRNAs, and find that miRNAs act as modulators of mRNA-mRNA interactions rather than as on-off molecular switches. We demonstrate such an important modulatory role for miRNAs in the biology of CNA-devoid breast cancers, a common subtype in which the immune response is prominent. These findings represent a new framework for studying the biology of miRNAs in human breast cancer.
Similar articles
-
Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.Biomed Res Int. 2015;2015:746970. doi: 10.1155/2015/746970. Epub 2015 Apr 15. Biomed Res Int. 2015. PMID: 25961039 Free PMC article.
-
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643. BMC Genomics. 2013. PMID: 24059244 Free PMC article.
-
Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7413-7. doi: 10.1073/pnas.1304977110. Epub 2013 Apr 15. Proc Natl Acad Sci U S A. 2013. PMID: 23589849 Free PMC article.
-
MicroRNA involvement in the pathogenesis and management of breast cancer.J Clin Pathol. 2009 May;62(5):422-8. doi: 10.1136/jcp.2008.060681. J Clin Pathol. 2009. PMID: 19398594 Review.
-
Small players with big roles: microRNAs as targets to inhibit breast cancer progression.Curr Drug Targets. 2010 Sep;11(9):1059-73. doi: 10.2174/138945010792006762. Curr Drug Targets. 2010. PMID: 20545613 Free PMC article. Review.
Cited by
-
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.J Biol Chem. 2015 Apr 17;290(16):10555-67. doi: 10.1074/jbc.M114.624361. Epub 2015 Mar 3. J Biol Chem. 2015. PMID: 25737447 Free PMC article.
-
MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management.Noncoding RNA. 2015 Apr 20;1(1):17-43. doi: 10.3390/ncrna1010017. Noncoding RNA. 2015. PMID: 29861413 Free PMC article. Review.
-
Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer.Oncotarget. 2018 Jan 9;9(10):9030-9042. doi: 10.18632/oncotarget.24088. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507672 Free PMC article.
-
Differential microRNA expression is associated with androgen receptor expression in breast cancer.Mol Med Rep. 2017 Jan;15(1):29-36. doi: 10.3892/mmr.2016.6019. Epub 2016 Dec 9. Mol Med Rep. 2017. PMID: 27959398 Free PMC article.
-
VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.Oncogene. 2017 Sep 7;36(36):5199-5211. doi: 10.1038/onc.2017.4. Epub 2017 May 15. Oncogene. 2017. PMID: 28504716 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical